Clinical Trials Logo

Adult Diffuse Astrocytoma clinical trials

View clinical trials related to Adult Diffuse Astrocytoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT02186509 Completed - Adult Glioblastoma Clinical Trials

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Start date: January 30, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of alisertib when combined with fractionated stereotactic radiosurgery in treating patients with high-grade gliomas that have returned after previous treatment with radiation therapy (recurrent). Alisertib may stop the growth of tumor cells by blocking an enzyme needed for the cells to divide. Radiation therapy uses high energy x rays to kill tumor cells. Stereotactic radiosurgery uses special positioning equipment to send a single high dose of radiation directly to the tumor and cause less damage to normal tissue. Delivering stereotactic radiosurgery over multiple doses (fractionation) may cause more damage to tumor tissue than normal tissue while maintaining the advantage of its accuracy.

NCT ID: NCT01635283 Completed - Clinical trials for Recurrent Adult Brain Tumor

Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Start date: January 10, 2012
Phase: Phase 2
Study type: Interventional

The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors

NCT ID: NCT01417507 Completed - Clinical trials for Psychosocial Effects of Cancer and Its Treatment

Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery

Start date: October 2011
Phase: N/A
Study type: Observational

This trial studies the natural history of brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery. Learning about brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery may help doctors learn more about the disease and find better methods of treatment and on-going care.

NCT ID: NCT01119599 Completed - Adult Glioblastoma Clinical Trials

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation therapy in treating patients with newly diagnosed malignant glioma. Enzyme inhibitors, such as gamma-secretase/Notch signalling pathway inhibitor RO4929097, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving gamma-secretase/Notch signalling pathway inhibitor RO4929097 together with temozolomide and radiation therapy may kill more tumor cells.

NCT ID: NCT01051557 Completed - Adult Glioblastoma Clinical Trials

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Start date: January 27, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of temsirolimus when given together with perifosine and to see how well it works in treating patients with recurrent or progressive malignant glioma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as perifosine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus with perifosine may be an effective treatment for malignant glioma.

NCT ID: NCT01024907 Completed - Clinical trials for Recurrent Adult Brain Tumor

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

Start date: December 17, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the best way to give proton beam radiation therapy and to see how well it works in treating patients with low grade gliomas.

NCT ID: NCT00823459 Completed - Adult Mixed Glioma Clinical Trials

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Start date: January 23, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

NCT ID: NCT00499473 Completed - Adult Glioblastoma Clinical Trials

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00492089 Completed - Malignant Neoplasm Clinical Trials

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain for primary brain tumor, meningioma, or head and neck cancer.

NCT ID: NCT00112736 Completed - Adult Glioblastoma Clinical Trials

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.